NEW YORK (GenomeWeb News) - Gene Network Sciences will use its biological modeling software to assist CombinatoRx in drug efficacy and safety studies, GNS said last week.
 
Under the agreement, the companies will use GNS' reverse engineering/forward simulation software, which it calls REFSTM, to characterize the cellular mechanisms that can cause “synergistic interactions” between multi-target candidate drugs.
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Publication of He Jiankui's work on gene-edited infants would raise ethical concerns for journals, Wired and others report.

The New York Times reports that evidence linking trauma in one generation to epigenetic effects that influence subsequent generations may be overstated.

ScienceInsider reports that US National Institutes of Health researchers were told in the fall they could not obtain new human fetal tissue.

In PNAS this week: skin pigmentation evolution among KhoeSan, biomarkers for dengue virus progression, and more.